Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Geier

Showing results (11-20 of 249) with videos related to

Pageof 25
Sort By:
Hepatology (Baltimore, Md.)|September 20, 2017
Bile acids in nonalcoholic steatohepatitis: Pathophysiological driving force or innocent bystanders?Daniel Jahn, Andreas Geier
Journal of Hepatology|May 28, 2013
Reply to: "estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?"Monika Rau, Andreas Geier
Zeitschrift Fur Gastroenterologie|April 10, 2019
Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developmentsElke Roeb, Andreas Geier
Expert Opinion on Drug Metabolism & Toxicology|February 27, 2024
What is the impact of metabolic dysfunction-associated steatotic liver disease on drug transport and metabolism?Christoph G Dietrich, Andreas Geier
Lancet (London, England)|January 11, 2025
TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinomaFlorian P Reiter, Andreas Geier
Hepatology (Baltimore, Md.)|December 1, 2005
It takes more than one--is a single UGT polymorphism enough to bother detoxification?Christoph G Dietrich, Andreas Geier
Expert Opinion on Drug Metabolism & Toxicology|September 28, 2014
Effect of drug transporter pharmacogenetics on cholestasisChristoph G Dietrich, Andreas Geier
Medizinische Klinik (Munich, Germany : 1983)|January 13, 2004
[Regulation of hepatobiliary transporters in cholestatic liver disease]Andreas Geier, Carsten Gartung, Siegfried Matern
Deutsches Arzteblatt International|July 15, 2014
Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatmentJohannes Weiß, Monika Rau, Andreas Geier
Zeitschrift Fur Gastroenterologie|May 13, 2025
Major clinical overlap of the new and former definition of steatotic liver disease in Germany - evidence from the Wuerzburg Fatty Liver CohortAndreas Geier, Johanna Kestel, Monika Rau
Pageof 25

Showing results (11-20 of 249) with videos related to

Sort By:
Pageof 25
Hepatology (Baltimore, Md.)|September 20, 2017
Bile acids in nonalcoholic steatohepatitis: Pathophysiological driving force or innocent bystanders?Daniel Jahn, Andreas Geier
Journal of Hepatology|May 28, 2013
Reply to: "estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?"Monika Rau, Andreas Geier
Zeitschrift Fur Gastroenterologie|April 10, 2019
Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developmentsElke Roeb, Andreas Geier
Expert Opinion on Drug Metabolism & Toxicology|February 27, 2024
What is the impact of metabolic dysfunction-associated steatotic liver disease on drug transport and metabolism?Christoph G Dietrich, Andreas Geier
Lancet (London, England)|January 11, 2025
TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinomaFlorian P Reiter, Andreas Geier
Hepatology (Baltimore, Md.)|December 1, 2005
It takes more than one--is a single UGT polymorphism enough to bother detoxification?Christoph G Dietrich, Andreas Geier
Expert Opinion on Drug Metabolism & Toxicology|September 28, 2014
Effect of drug transporter pharmacogenetics on cholestasisChristoph G Dietrich, Andreas Geier
Medizinische Klinik (Munich, Germany : 1983)|January 13, 2004
[Regulation of hepatobiliary transporters in cholestatic liver disease]Andreas Geier, Carsten Gartung, Siegfried Matern
Deutsches Arzteblatt International|July 15, 2014
Non-alcoholic fatty liver disease: epidemiology, clinical course, investigation, and treatmentJohannes Weiß, Monika Rau, Andreas Geier
Zeitschrift Fur Gastroenterologie|May 13, 2025
Major clinical overlap of the new and former definition of steatotic liver disease in Germany - evidence from the Wuerzburg Fatty Liver CohortAndreas Geier, Johanna Kestel, Monika Rau
Pageof 25